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Abstract The clotting activity of human fibrinogen was fully
inhibited in vitro by peroxynitrite. The decrease of activity
followed an exponential function and the concentration of
peroxynitrite needed to inhibit 50% of fibrinogen clotting was
22 WM at 25‡C. The oxidative modification(s) induced by the
peroxynitrite system (i.e. ONOO3, ONOOH and ONOOH*)
appeared specifically to affect fibrin clot formation (through the
inhibition of fibrinogen polymerization) since the interaction of
peroxynitrite-modified fibrinogen with thrombin appeared to be
unaffected. The addition of NaHCO3 decreased the peroxynitrite
effect on fibrinogen clotting, suggesting that the reactive species
formed by the reaction of CO2 with peroxynitrite are less
efficient oxidants of peroxynitrite itself. Similar effects were
observed after addition of bilirubin, which also exerted a
significant protection against peroxynitrite-mediated modifica-
tion of fibrinogen.
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1. Introduction
Nitric oxide (NO) is a free radical messenger molecule
which plays a key role in several physiological processes,
such as neurotransmission, inhibition of platelet adherence
and aggregation, blood pressure control, neutrophil aggrega-
tion, blood clotting and oxidative modi¢cation of low density
lipoprotein in plasma [1^4]. On the other hand, many patho-
physiological processes, such as reperfusion of ischemic tissues
[5] and acute in£ammation [6], may be trigger events, which
stimulate NO production. Owing to its oxidative power, an
excessive amount of NO can induce, on biological systems,
undesirable e¡ects which are strongly increased by the reac-
tion with transition metals and oxygen active species [7^9]. In
this context, particular attention has been focused on the re-
action of NO with superoxide anion O32 , which is released by
a variety of cells such as endothelial cells, activated neutro-
phils and macrophages [10^13]. The combination of NO with
superoxide radicals (O32 ) produces several active species,
which are able to oxidize many cellular components. The
main end-product of this reaction is the peroxynitrite anion
(ONOO3), which, under physiological conditions, is in equi-
librium with the peroxynitrous acid (ONOOH), and rapidly
decays to nitrate through the formation of a very active
secondary species (i.e. ONOOH*). The peroxynitrite system
(i.e. ONOO3, ONOOH and ONOOH*) leads to a covalent
modi¢cation of several amino acid residues in proteins, such
as cysteine, methionine, tryptophan and tyrosine residues
[8,14^16]. Therefore, since the rate of peroxynitrite formation
depends on the product of O32 and NO
 concentrations, even
a relatively small increase of one or both species may result in
a remarkable increase of peroxynitrite formation up to poten-
tially cytotoxic levels. Evidence for a role of ONOO3 in vivo
is largely based upon detection of modi¢ed tyrosine residues
(as 3-nitrotyrosine) in the biological system, even though the
presence of anti-oxidizing agents, such as ascorbic acid, thiols
and uric acid, inhibits peroxynitrite-induced oxidation [17].
The levels of nitrated proteins in plasma of healthy subjects
are normally low, but they drastically increase in patients with
acute lung injury and atherosclerosis [18^21], and even low
concentrations of peroxynitrite (of about 1^1.5 mM) have
been shown to induce in vitro a large tyrosine nitration of
bovine serum albumin and ¢brinogen [22] with possible rele-
vance for their biological properties. These e¡ects appear to
be related to either a direct interaction of peroxynitrite (and/
or its derivatives) with these plasma components and/or to a
synergistic action with the highly unstable nitrosoperoxycar-
bonate (ONO2CO32 ). This product which originates from the
reaction of peroxynitrite with CO2 (see below, reaction 1)
seems to protect protein molecules from various oxidative
damage induced by peroxynitrite (in particular from the
^SH oxidation), but, at the same time, it stimulates, in a
concentration-dependent manner, nitration of tryptophan
and tyrosine residues on some plasma proteins, mainly on
serum albumin and, with lesser e¡ects, on ¢brinogen [22,23].
The latter protein, which represents about 4% of the total
plasma proteins and plays a key role in the clotting cascade,
appears particularly susceptible to the e¡ect of oxidative com-
pounds; in fact, exposure of ¢brinogen to the Fe2/ascorbate
system leads to a signi¢cant decrease of clotting activity [24].
In this paper, we show that a similar e¡ect can be obtained
when ¢brinogen interacts with physiological concentrations of
peroxynitrite and that this inhibitory e¡ect can be antagonized
by CO2 and bilirubin.
2. Materials and methods
2.1. Materials
Human ¢brinogen was puri¢ed by human plasma as described by
Bharat et al. [25]. Its concentration was determined spectrophotomet-
rically at 280 nm using an extinction coe⁄cient of 1.5 for 1 mg/ml
solution. Human thrombin (3000 U/mg), was purchased from Sigma
(USA). Bilirubin was obtained from Aldrich (USA). All other re-
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agents were of the highest purity grade and used without further
puri¢cation.
2.2. Synthesis of peroxynitrite
Peroxynitrite was prepared from the reaction between H2O2 and
NaNO2, as described elsewhere [22]. The ¢nal solution was treated
with manganese dioxide to remove the excess of H2O2 and then ¢l-
tered twice. The concentration of peroxynitrite was determined meas-
uring the absorbance of the solution at 302 nm (O= 1670 M31 cm31)
[26]. The frozen stock solution was stored for 3^4 weeks at 340‡C
with negligible changes in its concentration. Immediately before use,
the stock solution was diluted in sodium hydroxide 100 mM and,
during the experiments, was maintained in an ice bath.
2.3. Clotting experiments
The thrombin-induced clotting of ¢brinogen was measured spectro-
photometrically, following the increase in absorbance at 350 nm as a
function of time, in a Cary 1 dual-beam spectrophotometer, thermo-
stated at 25‡C. Fibrinogen was incubated for 1 min in 100 mM phos-
phate bu¡er pH 7.1, 0.1 mM diethylenetriamine penta-acetic acid
(DPTC) with di¡erent amounts of peroxynitrite and clot formation
was triggered by addition of 1.2 units of human thrombin. Clotting
curves were analyzed as described in [27]. The e¡ect of CO2 on the
peroxynitrite-mediated ¢brinogen oxidation was studied by addition
of increasing amounts of NaHCO3 to the ¢brinogen sample 2 min
before addition of peroxynitrite (in order to account for the CO2
hydration and dehydration equilibration, which has a half time of
25 s over the pH range 7^8 [28]). Similarly, the e¡ect of bilirubin
was evaluated by incubating increasing amounts of bilirubin with
¢brinogen for 2 min before addition of peroxynitrite and the clotting
activity was evaluated as described above. Stock solutions of bilirubin
were kept in NaOH 0.1 M and their concentration was determined
spectrophotometrically at 435 nm (O435 = 40.9 þ 0.4 mM31 cm31). The
eventual presence of biliverdin was determined by the absorbance at
670 nm (O670 = 0.17 þ 0.01 mM31 cm31) [22].
3. Results and discussion
The e¡ect of peroxynitrite on ¢brinogen clotting induced by
human thrombin is shown in Fig. 1. Increasing amounts of
peroxynitrite decreased the rate of ¢brinogen polymerization
Fig. 1. E¡ect of peroxynitrite on ¢brinogen clotting induced by human thrombin. A: E¡ect of increasing amounts of peroxynitrite (0, (0); (1) 2
WM; (2) 8 WM; (3) 16 WM; (4) 21 WM; (5) 32 WM; (6) 56 WM) on ¢brinogen clotting time. Fibrinogen (0.5 WM) was incubated at 25‡C for
1 min in 50 mM phosphate bu¡er pH 7.1 after addition of peroxynitrite. Clotting was followed at 350 nm after addition of 1.2 units of human
thrombin. B: Line 1, inhibition of ¢brinogen clotting (b) (expressed as the t0c /t
i
c ratio) as function of peroxynitrite concentration. The experi-
ments were performed as reported in (A). For the t0c and t
i
c signi¢cance, see text. Line 2 refers to the e¡ect of the peroxynitrite decomposition
products on ¢brinogen clotting (a). At this end, di¡erent amounts of peroxynitrite were incubated for 1 min in 50 mM phosphate bu¡er pH
7.1 before addition of ¢brinogen (0.5 WM). After another minute, human thrombin (1.2 U), was added and clotting activity measured as re-
ported in (A). C: E¡ect of the peroxynitrite decomposition products on the amidolytic activity of human thrombin. Increasing amounts of per-
oxynitrite were incubated for 1 min in 50 mM phosphate bu¡er pH 7.1. Human thrombin (0.12 U) was added to the solution, incubated for
1 min and the amidolytic activity of the enzyme was measured at 405 nm following the hydrolysis of 13 WM of Tos-Gly-Pro-Arg-pNA
(Chromozym-TH) [31].
Fig. 2. SDS-PAGE (10%) of ¢brinopeptides generated by the action
of human thrombin on native (lanes 2^5) and peroxynitrite-treated
(lanes 6^8) ¢brinogen at di¡erent incubation times. Lane 1 refers to
time point zero (urea added at ¢brinogen prior to thrombin). Ali-
quots of the incubation mixture were withdrawn at 2 min (lanes 2),
5 min (lanes 3 and 6), 10 min (lanes 4 and 7) and 20 min (lanes 5
and 8), the reaction was stopped by addition of 5 M urea.
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(expressed as increase of absorbance at 350 nm, see Fig. 1A),
this lead to an increase of the clotting time (tc), that is the
interval required for the formation of the polymer (see Fig.





c is the clotting time in the absence of peroxyni-
trite and tic is the clotting time in the presence of the concen-
tration i of peroxynitrite) appeared to be correlated to the
concentration of peroxynitrite, reaching W100% inhibition
at 60 WM peroxynitrite (see Fig. 1B). As expected, because
of the peroxynitrite instability the inhibitory e¡ect was not
a¡ected by an increase in the incubation time of peroxynitrite
with ¢brinogen, and it reached its maximum value within
1 min of incubation time.
The inhibitory e¡ect appeared speci¢cally related to the
oxidative action of peroxynitrite since it occurred also when
0.1 mM DTPC was present in the reaction bu¡er, this allowed
us to rule out the possibility that the clotting inhibition was
due to oxidative phenomena induced on ¢brinogen by metal-
catalyzed reactions. Furthermore, no e¡ect of the decomposi-
tion products of peroxynitrite on the enzymatic activity of
thrombin could be detected (see Fig. 1B,C), this eliminated
also the possibility that the observed di¡erences in clotting
activity were linked to an unspeci¢c e¡ect on the thrombin
function. Finally, the peroxynitrite e¡ect on ¢brinogen clot-
ting activity did not seem to be derived from an impairment of
its interaction with thrombin and the production of ¢brino-
Fig. 3. E¡ect of increasing amounts (from 0 to 0.4 mM) of peroxynitrite on the UV di¡erence spectra of ¢brinogen (A). Measurements were
performed at 25‡C using 1.5 WM ¢brinogen in 50 mM potassium phosphate bu¡er at pH 7.1. B,C: The absorbance change at 251 nm and 280
nm, respectively, determined by the presence of increasing (from 0 to 0.4 mM) amounts of peroxynitrite.
Fig. 4. E¡ect of increasing amounts of NaHCO3 (A) and bilirubin (B) on the inhibition of ¢brinogen clotting induced by peroxynitrite. A: The
experiments were performed in absence (b) and in presence of 10 WM (a) and 15 WM (F) NaHCO3, respectively. The curve (E) was obtained
in the contemporary presence of 20 mM NaHCO3 and 15 WM bilirubin. B: the experiments were performed in absence (b) and in presence of
5 (a) and 15 WM (F) bilirubin, respectively. The curve (E) was obtained in the contemporary presence of 20 mM NaHCO3 and 15 WM biliru-
bin. 0.5 WM Fibrinogen was incubated with NaHCO3, bilirubin, or both the reagents, for 2 min before addition of peroxynitrite. Clotting activ-
ity was measured as described in the legend of Fig. 1.
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peptides, as results from the SDS gel-electrophoresis, dis-
played in Fig. 2, where the behavior of untreated and peroxy-
nitrite-treated ¢brinogen is compared. In fact, the exposure of
¢brinogen to peroxynitrite did not alter the production of
¢brinopeptides (AK and BL) by thrombin, suggesting that
the observed e¡ect was most likely ascribable to a defective
polymerization of ¢brinopeptides rather than to a defective
proteolysis by thrombin. This was further con¢rmed by the
observation that the clotting time ratio t0c /t
i
c was independent
of the thrombin concentration used in the assay (data not
shown).
Therefore, it appeared evident that the peroxynitrite-in-
duced alteration of clotting time (see Fig. 1) was related to
a speci¢c e¡ect on the ¢brinogen molecule. Thus, increasing
concentrations of peroxynitrite brought about modi¢cations
of the ¢brinogen UV spectra (Fig. 3A), which were character-
ized by an increase of the absorbance at 280 nm and a de-
crease at 251 nm. These spectral changes were linearly de-
pendent on the peroxynitrite concentration (see Fig. 3B,C),
this clearly indicated an interaction between ¢brinogen and
ONOO3, which brought about some structural alteration of
the protein (the slight increase of pH by W0.1 pH unit upon
addition of peroxynitrite was not responsible for the spectral
changes observed). Such a spectroscopic alteration in the 250^
270 nm range should be attributed to a speci¢c reaction with
an aromatic amino acid residue, most likely a tyrosine. There-
fore, this observation suggested that a peroxynitrite-linked
alteration of a tyrosyl residue(s) caused a drastic functional
modi¢cation of ¢brinogen, such that polymerization of ¢bri-
nopeptides was severely impaired.
In order to have more insight into the physiological signi¢-
cance of the peroxynitrite-induced e¡ect, and possibly into the
mechanism of protein modi¢cation, we have investigated the
e¡ect of blood components, such as CO2 and bilirubin, on the
phenomenon described. In fact, CO2 (whose concentration in
the plasma ranges around 1.3 mM) was in equilibrium with
HCO33 (at a concentration of about 25 mM) and it may react
in blood plasma with peroxynitrite through a fast reaction,
leading to the formation of a highly reactive oxidizing nitro-
soperoxycarbonate
ONOO3  CO2HONO2CO32 reaction 1
that rapidly decomposes. This secondary oxidizing agent may
either increase (acting synergistically) or inhibit (consuming
ONOO3) the oxidative damage induced by peroxynitrite on
plasma proteins [29]. The addition of 10 mM NaHCO3 to the
incubation mixture reduced by W41% the peroxynitrite-medi-
ated inhibition of ¢brinogen’s clotting activity (Fig. 4A) and
this in spite of the fact that HCO33 itself partially inhibits the
clotting activity [30]. Therefore, the results reported in Fig. 4A
clearly indicated that the occurrence of reaction 1 (which is
favored by the addition of HCO33 ) resulted in a partial re-
moval of the agent speci¢cally responsible for the inactivation
of ¢brinogen (i.e. ONOO3), further strengthening the hypoth-
esis that peroxynitrite is by far and large the major factor
a¡ecting the clotting activity of ¢brinogen.
In addition, the e¡ect of bilirubin on peroxynitrite-induced
inhibition of clotting was investigated. Bilirubin is a pigment,
derived from heme catabolism (its concentration in plasma
ranges around 15^20 WM), which is preferentially bound to
albumin and is reported to play an important role as a phys-
iological secondary anti-oxidizing agent against the reactive
oxygen species [22]. We observed that addition of bilirubin
to the reaction mixture protected ¢brinogen from the peroxy-
nitrite-induced oxidation with a recovery of clotting activity of
W29% (see Fig. 4B). Finally, the simultaneous addition of
NaHCO3 (20 mM) and bilirubin (15 WM) resulted in a syner-
gistic action enhancing the protection of ¢brinogen against
peroxynitrite damage and brought about a 47% recovery of
clotting activity (expressed as clotting time; see Fig. 4B).
In conclusion, a direct interaction of ¢brinogen with per-
oxynitrite could be observed, such that a drastic inhibition of
clotting activity occurred even at very low ONOO3 concen-
trations (i.e. 1^25 WM). This e¡ect, which is mostly due to a
chemical modi¢cation of tyrosyl residue(s), impairing the
polymerization of ¢brinopeptides, is signi¢cantly reduced by
the presence of anti-oxidizing agents, such as CO2 and
bilirubin, which act synergistically. These results taken to-
gether indicate that, under particular pathological conditions,
the coagulative process could be impaired by an increase of
the peroxynitrite levels through a rapid and irreversible chem-
ical modi¢cation of ¢brinogen, and that the use of anti-
oxidants, also in association with more speci¢c drugs, could
be an important therapeutic tool for the control of peroxy-
nitrite endogenous toxicity.
Acknowledgements: The ¢nancial support of the University of Camer-
ino for this work is gratefully acknowledged.
References
[1] Moncada, G. (1992) Acta Physiol. Scand. 145, 201^227.
[2] Gaboury, J., Woodman, R., Granger, D., Reinhart, P. and Ku-
ber, P. (1993) Am. J. Physiol. 265, H826^H867.
[3] Nathan, C. (1992) FASEB J. 6, 3051^3066.
[4] Hazen, S.L., Hsu, F.F., Gaut, J.P., Crowley, J.R. and Heineker,
J.W. (1999) Methods Enzymol. 300, 88^105.
[5] Kaur, H. and Halliwell, B. (1994) FEBS Lett. 350, 9^12.
[6] Szabo', C. (1996) Shock 6, 79^88.
[7] Radi, R., Beckman, J.S., Bush, K. and Freeman, B.A. (1991)
J. Biol. Chem. 266, 4244^4250.
[8] Beckmann, L.-S., Beckmann, T.W., Chen, J., Marshall, P.A. and
Freeman, B.A. (1990) Proc. Natl. Acad. Sci. USA 87, 1620^
1624.
[9] Noronha-Dutra, A.A., Epperlain, M.M. and Woolf, N. (1993)
FEBS Lett. 321, 59^62.
[10] Ischiropoulos, H., Zhu, L. and Beckman, J.S. (1992) Arch. Bio-
chem. Biophys. 298, 446^457.
[11] Carreras, M.C., Pargament, G.A., Catz, S.D., Poderoso, J.J. and
Baveris, A. (1994) FEBS Lett. 341, 65^68.
[12] Kooy, N.W. and Royall, J.A. (1994) Arch. Biochem. Biophys.
310, 352^359.
[13] Hu'hmer, A.F.R., Gerber, N.C., Ortiz de Mantellano, P.R. and
Schoneich, C. (1996) Chem. Res. Toxicol. 9, 484^491.
[14] Huie, R.E. and Padmaja, S. (1993) Free Radic. Res. Commun.
18, 195^199.
[15] Eiserich, J.P., Hristova, M., Cross, C.E., Jones, D.D., Freeman,
B.A., Halliwell, B. and Von der Vliet, A. (1998) Nature 391, 393^
397.
[16] Bredt, D.S. and Synder, S. (1994) Annu. Rev. Biochem. 63, 125^
195.
[17] Arteel, G.E., Briviba, K. and Sies, H. (1999) FEBS Lett. 445,
226^230.
[18] Khan, J., Brennan, D.M., Bradley, N., Gao, B., Bruckdorfer, R.
and Jacobs, M. (1998) Biochem. J. 330, 795^801.
[19] Haddad, I.Y., Pataki, G., Hu, P., Galliani, C., Beckman, J.S. and
Matalon, S. (1994) J. Clin. Invest. 94, 2407^2413.
[20] Kaoy, N.N., Royal, J.A., Ye, Y.Z., Kelly, D.R. and Beckman,
J.S. (1995) Am. J. Respir. Crit. Care Med. 151, 1250^1254.
[21] Lefer, D.J., Scalia, R., Campbell, B., Nossuli, T., Hayward, R.,
FEBS 22933 26-11-99
G. Lupidi et al./FEBS Letters 462 (1999) 236^240 239
Salamon, M., Grayson, J. and Lefer, A.M. (1997) J. Clin. Invest.
99, 684^691.
[22] Minnetti, M., Mallozzi, C., Di Stasi, M.A. and Petraforte, D.
(1998) Arch. Biochem. Biophys. 352, 165^174.
[23] Pietraforte, D. and Minetti, M. (1997) Biochem. J. 321, 743^750.
[24] Schacter, E., Williams, J.A. and Levine, R.L. (1995) Free. Radic.
Biol. Med. 18, 815^821.
[25] Bharat, V.P. and Budzynski, A.Z. (1984) Biochemistry 23, 460^
470.
[26] Beckman, J.S., Chen, J., Ischiropulos, H. and Crow, J.P. (1994)
Methods Enzymol. 233, 229^240.
[27] De Cristofaro Di Cera, E. (1991) J. Protein Chem. 10, 455^468.
[28] Padmaja, S., Squadrito, L.C. and Pryor, W.A. (1998) Arch. Bio-
chem. Biophys. 349, 1^6.
[29] Berlett, B.S., Levine, L.R. and Stadtman, R.E. (1998) Proc. Natl.
Acad. Sci. USA 95, 2784^2789.
[30] Wang, D.W. (1980) J. Pharm. Sci. 69, 978^980.
[31] Stone, S. and Hofsteenge, J. (1986) Biochemistry 25, 4622^4628.
FEBS 22933 26-11-99
G. Lupidi et al./FEBS Letters 462 (1999) 236^240240
